Lupin receives approval from USFDA for Oseltamivir Phosphate

21 Feb 2018 Evaluate

Lupin has received final approval for its Oseltamivir Phosphate for Oral Suspension from the United States Food and Drug Administration (USFDA) to market the generic version of Hoffman-La Roche, Tamiflu for Oral Suspension, 6 mg/mL. Oseltamivir Phosphate had annual sales of approximately Rs 35.80 crore in the US.

Oseltamivir Phosphate is for treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and prophylaxis of influenza A and B in patients 1 year and older.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×